Bariatric surgery in class i obesity: A position statement from the international federation for the surgery of obesity and metabolic disorders (IFSO)

Obesity Surgery

Volumn 24, Issue 4, 2014, Pages 487-519

  Busetto, Luca ^a   Dixon, John ^b   De Luca, Maurizio ^c   Shikora, Scott ^d   Pories, Walter ^e,f   Angrisani, Luigi ^g  

^a UNIVERSITY OF PADOVA   (Italy)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c SAN BORTOLO HOSPITAL   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e EAST CAROLINA UNIVERSITY   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g San Giovanni Bosco Hospital   (Italy)

Author keywords

BMI; Class I obesity; Eligibility

Indexed keywords

AGE; ARTICLE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT DISORDER; CLASS I OBESITY; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COMORBIDITY; CONSENSUS; DISEASE COURSE; ECONOMIC ASPECT; ETHICS; ETHNICITY; GENERAL DEVICE; HEALTH CARE ORGANIZATION; HUMAN; LIFESTYLE MODIFICATION; LOW CALORY DIET; META ANALYSIS (TOPIC); METABOLIC DISORDER; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; RISK ASSESSMENT; SAFETY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW (TOPIC); WEIGHT CONTROL; WEIGHT REDUCTION; ADVERSE EFFECTS; CLASSIFICATION; CONSENSUS DEVELOPMENT; LIFESTYLE; METABOLIC DISEASES; OBESITY, MORBID; TREATMENT OUTCOME;

ANTIOBESITY AGENT;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BODY MASS INDEX; COMORBIDITY; HUMANS; LIFE STYLE; METABOLIC DISEASES; OBESITY; OBESITY, MORBID; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84897990965     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1214-1     Document Type: Article

References (175)

1. Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metrics. 2012;10:22.
2. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007;121:492-6.
3. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol. 2013;9:13-27.
4. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.
5. Finkelstein EA, Brown DS, Wrage LA, et al. Individual and aggregate years-of-life-lost associated with overweight and obesity. Obesity. 2010;18:333-9.
6. Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364:719-29.
7. WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-63.
8. Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308:581-90.
9. Jerant A, Franks P. Body mass index, diabetes, hypertension, and short-term mortality: a population-based observational study, 2000-2006. J Am Board Fam Med. 2012;25:422-31.
10. Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2012;162:20-6.
11. Kokkinos P, Myers J, Faselis C, et al. BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care. 2012;35:1021-7.
12. Tseng CH. Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;226:186-92.
13. The Look AHEAD Research Group. Cardiovascular effects of intesive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145-54.
14. Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. A systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg. 2011;253:484-7.
15. Amundson DE, Djurkovic S, Matwiyoff GN. The obesity paradox. Crit Care Clin. 2010;26:583-96.
16. Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep. 2010;12:120-6.
17. Oreopoulos A, Kalantar-Zadeh K, Sharma AM, et al. The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med. 2009;25:643-59.
18. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481-6.
19. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-9.
20. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219-34.
21. Lindström D, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet. 2006;368:1673-9.
22. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374:1677-86.
23. Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207:928-34.
24. Livingston EH, Chandalia M, Abate N. Do current body mass index criteria for obesity surgery reflect cardiovascular risk? Surg Obes Relat Dis. 2007;3:577-85.
25. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol. 2010;316:104-8.
26. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.
27. Keating CL, Peeters A, Swinburn BA, et al. Utility-based quality of life associated with overweight and obesity: the Australian diabetes, obesity, and lifestyle study. Obesity. 2013;21:652-5.
28. Kolotkin RL, Crosby RD, Pendleton R, et al. Health-related quality of life in patients seeking gastric bypass surgery vs non-treatment-seeking controls. Obes Surg. 2003;13:371-7.
29. Everson SA, Maty SC, Lynch JW, et al. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J Psychosom Res. 2002;53:891-5.
30. Colles SL, Dixon JB, O'Brien PE. Binge eating disorder: prevalence and correlates in sub-groups of the Australian population. Asia Pac J Clin Nutr. 2005;14:S109.
31. McCrea RL, Berger YG, King MB. Body mass index and common mental disorders: exploring the shape of the association and its moderation by age, gender and education. Int J Obes. 2012;36:414-21.
32. Seidell JC. Societal and personal costs of obesity. Exp Clin Endocrinol Diabetes. 1998;106:7-9.
33. Finkelstein EA, Di Bonaventura M, Burgess SM, et al. The costs of obesity in the workplace. J Occup Environ Med. 2010;52:971-6.
34. National Institutes of Health National Institutes of Health. National Heart, Lung and Blood Institute: clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. The Evidence Report, June 1998.
35. National Institute for Health and Clinical Excellence. Obesity. Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE Clin Guidelines. 2006;43:1-84.
36. Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317-35.
37. Tuomilehto J, Lindström D, Eriksson GE, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
38. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
39. Rawal LB, Tapp RJ, Williams ED, et al. Prevention of type 2 diabetes and its complications in developing countries: a review. Int J Behav Med. 2012;19:121-33.
40. The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. One-year results of the Look AHEAD trial. Diabetes Care. 2007;30:1374-83.
41. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individual with type 2 diabetes mellitus. Four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566-75.
42. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489-96.
43. Heymsfield SB, van Mierlo CA, van der Knaap HC, et al. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003;27:537-49.
44. Chearskul S, Delbridge E, Shulkes A, et al. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr. 2008;87:1238-46.
45. Mulholland Y, Nicokavoura E, Broom J, et al. Very-low-energy diets and morbidity: a systematic review of longer-term evidence. Br J Nutr. 2012;108:832-51.
46. Baker S, Jerums PJ. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. Diabetes Res Clin Pract. 2009;85:235-42.
47. Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579-84.
48. Anderson JW, Vichitbandra S, Qian W, et al. Long-term weight maintenance after an intensive weight-loss program. J Am Coll Nutr. 1999;18:620-7.
49. Lantz H, Peltonen M, Agren L, et al. Intermittent versus on-demand use of a very low calorie diet: a randomized 2-year clinical trial. J Intern Med. 2003;253:463-71.
50. Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84:304-11.
51. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71-7.
52. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-73.
53. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
54. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245-56.
55. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo controlled, phase 3 trial. Lancet. 2011;377:1341-52.
56. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308.
57. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595-605.
58. Apovian C, Aronne L, Rubino D, et al. A randomized, phase 3 trial of Naltrexone SR/Bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935-43.
59. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
60. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
61. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606-16.
62. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843-54.
63. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15:1161-4.
64. Verdam FJ, Schouten R, Greve JW, et al. An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery. J Obes. 2012;2012:597871.
65. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the endobarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251:236-43.
66. Sandler BJ, Rumbaut R, Swain CP, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc. 2011;25:3028-33.
67. Gastrointestinal surgery for severe obesity. National Institutes of Health consensus development conference draft statement. Obes Surg 1991;1:257-66.
68. Fried M, Hainer V, Basdevant A, et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes. 2007;31:569-77.
69. Rubino F, Kaplan LM, Schauer PR, et al. The diabetes surgery summit consensus conference recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399-405.
70. American Diabetes Association. Summary of revisions for the 2009 clinical practice recommendations. Diabetes Care. 2009;32:S3-5.
71. Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med. 2011;28:628-42.
72. Australian Government - National Health and Medical Research Council - Department of Health and Ageing. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia, 2013.
73. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient - 2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2013;9:159-91.
74. 2). Surg Obes Relat Dis. 2013;9:e1-e10.
75. Müller MJ, Lagerpusch M, Enderle J, et al. Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obes Rev. 2012;13:6-13.
76. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes. 2010;34:791-9.
77. Thomas EL, Frost G, Taylor-Robinson SD, et al. Excess body fat in obese and normal-weight subjects. Nutr Res Rev. 2012;25:150-61.
78. Kragelund C, Omland T. A farewell to body-mass index? Lancet. 2005;366:1589-91.
79. Deurenberg P, Deurenberg-Yap M. Validity of body composition methods across ethnic population groups. Forum Nutr. 2003;56:299-301.
80. Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol. 2005;98:944-8.
81. Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and in hospital mortality for 109,927 patients in the acute decompensated heart failure national registry. Am Heart J. 2007;153:74-81.
82. Oreopoulos A, Padwal R, Kalantar-zadeh K, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156:13-22.
83. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005;46:489-500.
84. Galal W, van Gestel YR, Hoeks SE, et al. The obesity paradox in patients with peripheral arterial disease. Chest. 2008;134:925-30.
85. Hastie CE, Padmanabhan S, Slack R, et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31:222-6.
86. Diercks D, Roe MT, Mulgund J, et al. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart Association guidelines quality improvement initiative. Am Heart J. 2006;152:140-8.
87. Mullen JT, Moorman DW, Davenport DL. The obesity paradox. Ann Surg. 2009;250:166-72.
88. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144:5159-65.
89. Montani JP, Carroll JF, Dwyer TM, et al. Ectopic fat storage in the heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord. 2004;28:S58-65.
90. Matsuzawa Y, Nakamura T, Shimomura I, et al. Visceral fat accumulation and cardiovascular disease. Obes Res. 1995;3:S645-7.
91. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-7.
92. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609-16.
93. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factors clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168:1617-24.
94. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. IDF Publications 2005.
95. Heitmann BL, Lissner L. Hip hip hurrah! Hip size inversely related to heart disease and total mortality. Obes Rev. 2011;12:478-81.
96. Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061-7.
97. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106:15430-5.
98. Iacobellis G, Malavazos AE, Corsi MM. Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol. 2011;43:1651-4.
99. Pories WJ, Dohm LG, Mansfield CJ. Beyond the BMI: the search for better guidelines for bariatric surgery. Obesity. 2010;18:865-71.
100. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33:289-95.
101. Padwal RS, Pajewski NM, Allison DB, et al. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183:E1059-66.
102. Kuk JL, Ardern CI, Church TS, et al. Edmonton obesity staging system: association with weight history and mortality risk. Appl Physiol Nutr Metab. 2011;36:570-6.
103. Gill RS, Karmali S, Sharma AM. The potential role of the Edmonton obesity staging system in determining indications for bariatric surgery. Obes Surg. 2011;21:1947-9.
104. Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621-35.
105. Thomas H, Agrawal S. Systematic review of obesity surgery mortality risk score - preoperative risk stratification in bariatric surgery. Obes Surg. 2012;22:1135-40.
106. The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-54.
107. De Maria EJ, Portenier D, Wolfe L. Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass. Surg Obes Relat Dis. 2007;3:134-40.
108. Blackstone RP, Cortes MC. Metabolic acuity score: effect on major complications after bariatric surgery. Surg Obes Relat Dis. 2010;6:267-73.
109. Turner PL, Saager L, Dalton J, et al. A nomogram for predicting surgical complications in bariatric surgery patients. Obes Surg. 2011;21:655-62.
110. O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med. 2006;144:625-33.
111. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-23.
112. Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146:143-8.
113. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;26(366):1567-76.
114. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y Gastric Bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. The diabetes surgery study randomized clinical trial. JAMA. 2013;309:2240-9.
115. 2. Diabetes Obes Metab. 2012;14:262-70.
116. 2. Surg Obes Relat Dis. 2010;6:332-8.
117. Huang CK, Shabbir A, Lo CH, et al. Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25-35. Obes Surg. 2011;21:1344-9.
118. 2. Obes Surg. 2011;21:283-7.
119. Cohen R, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-8.
120. Ferzli GS, Dominique E, Ciaglia M, et al. Clinical improvement after duodenojejunal bypass for nonobese type 2 diabetes despite minimal improvement in glycemic homeostasis. World J Surg. 2009;33:972-9.
121. Geloneze B, Geloneze SR, Fiori C. Surgery for nonobese type 2 diabetic patients: an interventional study with duodeno-jejunal exclusion. Obes Surg. 2009;19:1077-83.
122. 2 (LBMI). Obes Surg. 2009;19:307-12.
123. 2. Obes Surg. 2007;17:185-92.
124. 2. Diabetologia. 2009;52:1027-30.
125. 2): a prospective controlled study. Obes Surg. 2011;21:880-8.
126. 2. J Gastrointest Surg. 2008;12:945-52.
127. 2. Obes Surg. 2011;21:889-95.
128. De Paula AL, Macedo ALV, Schraibman V, et al. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. Surg Endosc. 2009;23:1724-32.
129. 2: a literature review. Diab Technol Ther. 2012;14(4):365-72.
130. Cohen R, Caravatto PP, Correa JL, et al. Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis. 2012;8:375-80.
131. 2. Rockville: Agency for Healthcare Research and Quality (US); 2013.
132. Parikh M, Issa R, Vieira D, et al. Role of bariatric surgery as treatment for type 2 diabetes in patients who do not meet current NIH criteria: a systematic review and meta-analysis. J Am Coll Surg. 2013;217:527-32.
133. Flum DR, Belle SH, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-54.
134. De Maria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the bariatric outcomes longitudinal database. Ann Surg. 2010;252:559-66.
135. 2. Surg Obes Relat Dis. 2006;2:518-22.
136. 2. Surg Endosc. 2009;23:1569-73.
137. Choi J, Digiorgi M, Milone L, et al. Outcomes of laparoscopic adjustable gastric banding in patients with low body mass index. Surg Obes Relat Dis. 2010;6:367-71.
138. 2). Surg Obes Relat Dis. 2009;5:425-8.
139. 2: sleeve gastrectomy versus medical treatment. Surg Obes Relat Dis. 2012;8:20-4.
140. 2. Obes Surg. 2004;14:415-8.
141. 2. Surgery. 2011;150:684-91.
142. 2: comparative analysis of 16 patients undergoing either BPD, BPD-DS, or RYGB. Obes Facts. 2011;4:13-7.
143. 2. Surg Obes Relat Dis. 2012;8:25-30.
144. Angrisani L, Cutolo PP, Formisano GP, et al. Long-term outcomes of laparoscopic adjustable silicone gastric banding (LAGB) in moderately obese patients with and without co-morbidities. Obes Surg. 2013;23:897-902.
145. Deitel M. Slow-progression, autoimmune, type 1 diabetes in adults: a cause of failure of resolution of diabetes after bariatric surgery. Surg Obes Relat Dis. 2009;5:705-6.
146. Deitel M. Update: why diabetes does not resolve in some patients after bariatric surgery. Obes Surg. 2011;21:794-6.
147. Wells JC. Ethnic variability in adiposity, thrifty phenotypes and cardiometabolic risk: addressing the full range of ethnicity, including those of mixed ethnicity. Obes Rev. 2012;13 Suppl 2:14-29.
148. WHO. Obesity: preventing and managing the global epidemic. Report of a who consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.
149. Inge TH, Krebs NF, Garcia VF, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics. 2004;114:217-23.
150. Baur LA, Fitzgerald DA. Recommendations for bariatric surgery in adolescents in Australia and New Zealand. J Paediatr Child Health. 2010;46:704-7.
151. Bannerman E, Miller MD, Daniels LA, et al. Anthropometric indices predict physical function and mobility in older Australians: the Australian longitudinal study of ageing. Public Health Nutr. 2002;5:655-62.
152. Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218-29.
153. Houston DK, Nicklas BJ, Zizza CA. Weighty concerns: the growing prevalence of obesity among older adults. J Am Diet Assoc. 2009;109:1886-95.
154. Zajacova A, Ailshire J. Body mass trajectories and mortality among older adults: a joint growth mixture-discrete-time survival analysis. Gerontologist 2013 Jan 25 [Epub ahead of print].
155. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23:427-36.
156. Picot J, Jones J, Colquitt JL, et al. Weight loss surgery for mild to moderate obesity: a systematic review and economic evaluation. Obes Surg. 2012;22:1496-506.
157. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211-9.
158. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. A systemic review and meta-analysis. JAMA. 2004;292:1724-37.
159. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515-29.
160. DePaula AL, Stival A, Halpern A, et al. Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI < 35: an analysis of 454 consecutive patients. World J Surg. 2011;35:102-8.
161. McKneally MF, Daar AS. Introducing new technologies: protecting subjects of surgical innovation and research. World J Surg. 2003;27:930-5.
162. Roman S, Napoleon B, Mion F, et al. Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539-44.
163. Champion JK, Williams M, Champion S, et al. Implantable gastric stimulation to achieve weight loss in patients with a low body mass index: early clinical results. Surg Endosc. 2006;20:444-7.
164. Afterburner DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23:93-102.
165. Ritz P, Hanaire H. Post-bypass hypoglycaemia: a review of the current findings. Diabetes Metab. 2011;37:274-81.
166. Lerner H, Whang J, Nipper R. Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc. 2013;27:702-7.
167. Reinhold RB. Critical analysis of long term weight loss following gastric bypass. Surg Gynecol Obstet. 1982;155:385-94.
168. Metropolitan height and weight tables. 64, 3-9. 1983. New York, Metropolitan Life Foundation. Statistical Bulletin
169. Committee on Standards for Reporting Results, American Society for Bariatric Surgery. Standards for reporting results. Obes Surg 1994;4:56-65.
170. Junior WS, Campos CS, Nonino CB. Reporting results after bariatric surgery: reproducibility of predicted body mass index. Obes Surg. 2012;22:519-22.
171. Deitel M, Gawdat K, Melissas J. Reporting weight loss. Obes Surg. 2007;17:565-8.
172. Belle SH, Berk PD, Courcoulas AP, et al. Reporting weight change: Standardized reporting accounting for baseline weight. Surg Obes Relat Dis. 2013;9:782-9.
173. Sabin J, Fanelli R, Flaherty H, et al. Best practice guidelines on informed consent for weight loss surgery patients. Obes Res. 2005;13:250-3.
174. Sarr MG, Billington CJ, Brancatisano R, et al. The EMPOWER study: randomized, prospective, double-blind, multicenter trail of vagal blockade to induce weight loss in morbid obesity. Obes Surg. 2012;11:1771-82.
175. Shikora SA, Bergenstal R, Bessler M, et al. Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. Surg Obes Relat Dis. 2009;5:31-7.